Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 129

Similar articles for PubMed (Select 23301228)

1.

A case with coexistence of major and minor BCR/ABL fusion transcript at lymphoblastic crisis of chronic myelogenous leukemia in patients with major BCR/ABL positivity during chronic phase.

Park SH, Chi HS, Cho YU, Jang S, Park CJ, Im HJ.

Ann Lab Med. 2013 Jan;33(1):80-3. doi: 10.3343/alm.2013.33.1.80. Epub 2012 Dec 17. No abstract available.

2.

Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.

Merx K, Müller MC, Kreil S, Lahaye T, Paschka P, Schoch C, Weisser A, Kuhn C, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A.

Leukemia. 2002 Sep;16(9):1579-83.

3.

Rare frameshift mutation Cys475Tyrfs(*)11 in the BCR/ABL kinase domain contributes to imatinib mesylate resistance in 2 Korean patients with chronic myelogenous leukemia.

Park SH, Chi HS, Kwon MR, Cho YU, Jang S, Park CJ.

Ann Lab Med. 2012 Nov;32(6):452-4. doi: 10.3343/alm.2012.32.6.452. Epub 2012 Oct 17. No abstract available.

4.

Molecular response in CML: where is the bar?

Baccarani M, Soverini S.

Blood. 2014 Jul 24;124(4):469-71. doi: 10.1182/blood-2014-06-578617. No abstract available.

5.

Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib.

Morel F, Bris MJ, Herry A, Calvez GL, Marion V, Abgrall JF, Berthou C, Braekeleer MD.

Eur J Haematol. 2003 Apr;70(4):235-9.

PMID:
12656747
6.

Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level?

Qin YZ, Jiang Q, Jiang H, Li JL, Li LD, Zhu HH, Lai YY, Lu XJ, Liu YR, Jiang B, Huang XJ.

Leuk Res. 2013 Sep;37(9):1035-40. doi: 10.1016/j.leukres.2013.06.003. Epub 2013 Jun 26.

PMID:
23810191
7.

Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib.

Branford S, Kim DW, Soverini S, Haque A, Shou Y, Woodman RC, Kantarjian HM, Martinelli G, Radich JP, Saglio G, Hochhaus A, Hughes TP, Müller MC.

J Clin Oncol. 2012 Dec 10;30(35):4323-9. doi: 10.1200/JCO.2011.40.5217. Epub 2012 Oct 29.

8.

[Detection and quantification of BCR-ABL transcripts in patients with chronic myeloid leukemia by real-time quantitative reverse transcriptase polymerase chain reaction].

Xing W, Gu BW, Zhu YM, Jiang CL, Zhao RH, Wang AH, Sun HP, Li JM, Shen ZX, Chen Z, Chen SJ.

Zhonghua Yi Xue Za Zhi. 2005 Feb 23;85(7):453-7. Chinese.

PMID:
15854550
9.

Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript.

Pienkowska-Grela B, Woroniecka R, Solarska I, Kos K, Pastwińska A, Konopka L, Majewski M.

Cancer Genet Cytogenet. 2007 Apr 15;174(2):111-5.

PMID:
17452251
10.

Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.

Lahaye T, Riehm B, Berger U, Paschka P, Müller MC, Kreil S, Merx K, Schwindel U, Schoch C, Hehlmann R, Hochhaus A.

Cancer. 2005 Apr 15;103(8):1659-69.

11.

[New strategies to overcome imatinib resistance in treatment for chronic myelocytic leukemia].

Liu H, Chen XG.

Zhonghua Zhong Liu Za Zhi. 2006 Aug;28(8):561-3. Review. Chinese. No abstract available.

PMID:
17236546
12.

Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia.

Donato NJ, Wu JY, Stapley J, Lin H, Arlinghaus R, Aggarwal BB, Shishodia S, Albitar M, Hayes K, Kantarjian H, Talpaz M.

Cancer Res. 2004 Jan 15;64(2):672-7. Erratum in: Cancer Res. 2004 Mar 15;64(6):2306. Shishodin, Shishir [corrected to Shishodia, Shishir].

13.

Chronic myeloid leukemia with a novel four-way t(6;13;9;22)(p21;q32;q34;q11.2) successfully treated with imatinib mesylate.

Kubota Y, Waki M.

Cancer Genet Cytogenet. 2010 Sep;201(2):135-6. doi: 10.1016/j.cancergencyto.2010.05.017. No abstract available.

PMID:
20682400
14.

A case of isolated lymphoblastic relapse of the central nervous system in a patient with chronic myelogenous leukemia treated with imatinib.

Park MJ, Park PW, Seo YH, Kim KH, Seo JY, Jeong JH, Kim MJ, Jeong JW, Ahn JY, Park J.

Ann Lab Med. 2014 May;34(3):247-51. doi: 10.3343/alm.2014.34.3.247. Epub 2014 Apr 8. No abstract available.

15.

BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib.

Gadzicki D, von Neuhoff N, Steinemann D, Just M, Büsche G, Kreipe H, Wilkens L, Schlegelberger B.

Cancer Genet Cytogenet. 2005 Jun;159(2):164-7.

PMID:
15899391
16.

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.

Hochhaus A, Kreil S, Corbin AS, La Rosée P, Müller MC, Lahaye T, Hanfstein B, Schoch C, Cross NC, Berger U, Gschaidmeier H, Druker BJ, Hehlmann R.

Leukemia. 2002 Nov;16(11):2190-6.

17.

Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.

Paschka P, Müller MC, Merx K, Kreil S, Schoch C, Lahaye T, Weisser A, Petzold A, König H, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A.

Leukemia. 2003 Sep;17(9):1687-94.

PMID:
12970765
18.

Ponatinib circumvents all types of imatinib resistance in chronic myelogenous leukemia cell lines.

Dufies M, Cassuto O, Jacquel A, Robert G, Auberger P.

Cell Cycle. 2013 Jun 1;12(11):1645-6. doi: 10.4161/cc.24982. Epub 2013 May 10. No abstract available.

19.

Molecular monitoring in patients with chronic myelogenous leukemia.

Saglio G, Ulisciani S, Fava M, Gottardi E, Cilloni D.

Curr Hematol Malig Rep. 2008 Apr;3(2):65-71. doi: 10.1007/s11899-008-0011-0.

PMID:
20425449
20.

Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients.

Bianchini M, De Brasi C, Gargallo P, Gonzalez M, Bengió R, Larripa I.

Eur J Haematol. 2009 Apr;82(4):292-300. doi: 10.1111/j.1600-0609.2008.01199.x. Epub 2008 Dec 17.

PMID:
19191867
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk